Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.

Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.

Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.

Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.

Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.

Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.

Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.

Abstract: The invention provides a method for grouping measurement data obtained by effecting two or more techniques to provide characterization data characterizing at least one sample with respect to characterizing substances. According to one aspect of the invention, the grouping is effected on the basis of at least one statistical distribution of deviations (?m/zi) of a respective characterizing measurement value. According to another aspect of the invention, the grouping is effected on the basis of at least one collective characteristic of a plurality of respective quantitative measurement values (Ii).

Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at least two different antibody sites.

Abstract: By deglycosylating an enzyme derived from a eukaryotic organism prior to forming a conjugate, i.e. prior to attaching the enzyme to a molecule capable of binding to a target molecule, the sensitivity of an assay for detecting the presence or determining the quantity of a target molecule, in which the conjugate is used as a labelled component, can be increased. The present invention provides conjugates, methods for providing the same, use of such conjugates as well as kits containing the conjugates.

Abstract: By deglycosylating an enzyme derived from a eukaryotic organism prior to forming a conjugate, i.e. prior to attaching the enzyme to a molecule capable of binding to a target molecule, the sensitivity of an assay for detecting the presence or determining the quantity of a target molecule, in which the conjugate is used as a labelled component, can be increased. The present invention provides conjugates, methods for providing the same, use of such conjugates as well as kits containing the conjugates.

Abstract: The invention concerns antibodies to special forms of enzymatically non-active precursors of prostate specific antigen (PSA), their production, their use in immunoassays for determination of [−5, −6, −7] proPSA and the use of measured values from these assays for improved diagnostics in the field of prostatic carcinoma.

Abstract: The invention concerns an immunological process for the determination of prostate-specific antigen (PSA), particularly for the determination of free PSA, the total concentration of PSA and the concentration of PSA-serpin complexes by incubation of the sample with at least one antibody specifically binding to free PSA but not to complex PSA. The process is characterized in that especially before the determination of the total PSA concentration a nucleophile containing amine is added to the sample. Furthermore, the invention concerns the use of amine-containing nucleophiles for the production of free PSA as well as a procedure for preparing free PSA from complex PSA by incubation of a sample containing complex PSA with a nucleophile containing amine.